New application of xinkeshu tablet

Abstract

The invention provides an application of a composition prepared from the following raw materials in preparing drugs for treating cholestatic hepatitis. The pharmaceutical composition is a preparation prepared from the following raw materials in parts by weight: 350-400 parts of hawthorns, 350-400 parts of salvia miltiorrhiza, 350-400 parts of radix pueraiae, 20-30 parts of panax notoginseng, and 20-30 parts of radix aucklandiae. According to the invention, research findings shows that xinkeshu medicaments have a good treatment effect on cholestatic liver diseases, and provide new choices for clinical medication.

Description

technical field [0001] The present invention relates to the new application of Xinkeshu. Background technique [0002] Cholestatic hepatitis is a clinical syndrome, common in infantile hepatitis syndrome, genetic metabolic diseases, primary biliary cirrhosis, sclerosing cholangitis and other diseases, if not treated in time, it will lead to cirrhosis and other diseases Serious consequences. Commonly used drugs for clinical treatment of cholestasis include ursodeoxycholic acid and corticosteroids, but their efficacy is not satisfactory. [0003] Xinkeshu is refined from five traditional Chinese medicines of Danshen, Pueraria lobata, Muxiang, Panax notoginseng and hawthorn. Standard number: WS3-B-2856-98, functions and indications: promoting blood circulation and removing blood stasis, promoting qi and relieving pain. It is used for chest tightness, angina pectoris, high blood pressure, dizziness, headache, neck pain, arrhythmia, and hyperlipidemia caused by qi stagnation a...

AI Technical Summary

Problems solved by technology

Commonly used clinical drugs for the treatment of cholestasis include ursod

Images